Description

The fund typically allocates at least 80% of its overall assets, augmented by any borrowed capital used for investment, to equity holdings of companies within the healthcare industry. A considerable portion of its capital is directed towards innovative, early-stage businesses in areas such as medical equipment and supplies, pharmaceuticals, biotechnology, and the broader life sciences, many of which have not yet achieved consistent profitability.